Human Immunodeficiency Virus (HIV) related Pneumocystis carinii pneumonia (PCP) associated with severe respiratory failure is an increasingly common problem in major centres and is associated with a high mortality in previous and recent studies. Early in the epidemic, alternatives to invasive intensive care treatment were utilized in our institution and found to be successful. When respiratory failure developed, mask CPAP was used instead of intubation and ventilation. A retrospective review of 175 cases of HIV infected patients with confirmed first presentation PCP was undertaken. Treatment with our protocol resulted in an overall hospital mortality of9%. Those patients who did not require supplemental oxygen or respiratory support had no in-hospital mortality. The group who required supplemental oxygen had a mortality of 1 0%. If respiratory failure supervened (severe respiratory distress, Pa02 < 50 mmHg, Sa02 < 90% on mask oxygen), CPAP was introduced. The mortality in this group was 22%. Only two patients were admitted to the intensive care unit for respiratory support after failure ofCPAP. Both patients were intubated and received intermittent positive pressure ventilation (IPPV). Both patients died.
The apparent improvement in prognosis and the increasing number of cases has led to an increased request for Intensive Care admission.
In 1986, Wachter reported that 73% of the medical house staff and 57% of the attending physicians at San Francisco General Hospital stated that mechanical ventilation was 'never' or 'rarely' indicated for HIV associated PCP. 5 In the light of this and the unwillingness of many patients to undergo invasive, uncomfortable and sometimes futile treatments, from 1987 onwards it was decided to employ CP AP in our HIV Medicine Ward for all patients who developed respiratory failure associated with PCP. CPAP by face mask was introduced to avoid airway invasion and reduce the risk of nosocomial infection in these immunocompromised patients. The aim was to optimize therapy while minimizing patient discomfort.
Preliminary results were encouraging, with respiratory function improving in the majority after five days' treatment so they were able to be weaned from CPAP. Patients and relatives were accepting of the treatment because their ability to communicate was not hampered. Requests and necessity for intubation and ventilation declined so the policy has continued. On the basis of these early findings, we undertook a retrospective review to formally evaluate the ward treatment protocol.
MATERIALS AND METHODS
Records of all patients with AIDS who had microbiologically confirmed first presentation PCP at St. Vincent's Hospital from June 1984 till February 1990 were reviewed (n = 175). Information on age, sex, risk factors, CD 4 cell count, source of referral, previous medical surveillance, method of PCP diagnosis, severity of illness on admission, respiratory rate, P a o 2 , Apache Score, respiratory support required, hospital course and discharge follow-up was sought.
There were 174 men and one woman. Of these, 173 were homosexual, one was an IV drug user and there was one patient who contracted HIV infection following a blood transfusion.
All patients were admitted to our HIV Medicine Ward. A provisional diagnosis ofPCP was made on the basis of fever, non-productive cough, dyspnoea and a chest X-ray revealing a diffuse interstitial infiltrate. P. carinii was demonstrated by standard techniques using the toluidine blue or methenamine silver stain in specimens obtained from either bronchoscopy with broncho-alveolar lavage or from sputum induced with nebulised 3% hypertonic saline.
If the patient was assessed by physical examination and arterial blood gases to be at risk of respiratory failure secondary to bronchoscopy, it was either postponed until it was considered safe to perform the procedure or diagnosis was achieved by induced sputum samples.
Standard medical therapy including antimicrobial therapy with cotrimoxazole or pentamidine was supervised by the attending physician. From 1989, high-dose intravenous corticosteroids were given early in the treatment regimen to all patients with P a o 2 less than 65 mmHg on room air.
Respiratory support was initiated according to the arterial oxygenation as assessed by the pulse oximeter (Sa02%) or arterial blood gas estimation (P a o 2 mmHg) and clinical picture. Patients were commenced on oxygen by standard facemask if they were in respiratory distress, if the Sa02 was less than 95% or if the P a o 2 was less than 70 mmHg on room air. If acute respiratory failure (ARF) developed then CP AP was commenced. ARF was defined as the inability to maintain P a o 2 greater than 50 mmHg or Sa02 greater than 90% on maximal flow 100% oxygen through a standard facemask. CPAP was commenced at 10 cm H 2 0 and titrated to produce an Sa02 greater than 90% with an Fi02 less than or equal to 0.5. Weaning to standard facemask was possible when the patient was able to sustain an Sa02 greater than 90% on 5 cm CPAP with an Fi02 less than 0.5.
Three groups of patients were identified: 1. nil added oxygen required; 2. oxygen by standard facemask only; 3. respiratory support via mask CP AP or intubation and ventilation.
If the patient did not improve or deteriorated on CPAP, then adjustments were made to the circuit to minimize pressure fluctations in the circuit and decrease the work of breathing (e.g. increasing gas flow, changing heat and moisture exchanger or adding reservoir volume), the CPAP level was increased and causes of worsening lung function (e.g. fluid overload, superinfection, pneumothorax) were sought and treated. Only two patients were intubated and ventilated when oxygenation was not sustained with CP AP and other therapeutic interventions. These patients are considered failures of CPAP therapy.
The CP AP circuit used is similar to that used in many centres. It consists of a Downs high flow generator (Anaesthetic Supplies Pty Ltd), a fourlitre reservoir bag in the inspiratory limb and a PEEP valve in the expiratory limb. FP2 is regulated by varying the entrainment of air at the flow generator and measured with an oxygen analyser in the inspiratory limb. The circuit pressure is constantly measured with an anaeroid gauge connected by tubing to the facemask. Patients were monitored with pulse oximetry. Patients in respiratory failure are not routinely admitted to the intensive care unit but are admitted to the HIV Medicine Ward where they are nursed as 'high dependency' patients by the nursing staff, who have now accumulated considerable experience with mask CPAP.
Data are expressed as the mean ± SEM. The Student's t-test and chi-square tests were used to assess the significance of the data obtained. A P value of less than 0.05 was considered to be statistically significant.
RESULTS

Demographic data
A total of 175 patients with first presentation PCP were reviewed. The average age was 37 years, average stay in hospital was twelve days and survival was 91 %. Patients were grouped according to the necessity for oxygen or respiratory support. Of the 175 patients, 53 required no supplementary O 2 (group I), 90 received 02 by standard face mask only (group 11) and 32 received O 2 via CP AP (group Ill). Two of these patients were intubated and ventilated after failure of CPAP. Table 1 demonstrates the severity of illness of all the patients as indicated by P a02 on presentation, respiratory rate, Apache 11 score and CD 4 cell count.
Patients in Group III demonstrate severe illness on presentation with mean Apache II Scores of 22 ± 0.8, respiratory rate 44 ± 1.5 and P a o 2 49 ± 2.1. Nineteen of these patients had arterial blood gases taken while breathing room air but thirteen patients had them taken while receiving supplemental oxygen by face mask due to the severity of their hypoxia. Of the nineteen patients who had room air blood gases, the mean P a02 was 47 ± 2.6. The mortality in the three groups and in two patients who required IPPV following CP AP failure is shown in Table 2 . The mortality in the group having CPAP for ARF was 21.9%. The patients who were intubated and ventilated both died. The decision to intubate and ventilate was made in both cases after a failure of CP AP and they are both included in the CP AP group. 
Cause of death
In the whole group reviewed, sixteen patients died (9.1 %). Nine patients died without receiving respiratory support (CPAP or IPPV). Death was related to other severe medical problems associated with the HIV infection. Eight of these patients had been regularly attending the outpatient clinics and had been extensively investigated and treated.
Seven patients died after receiving respiratory support (CP AP or IPPV). Two of these patients had been off CP AP for over two weeks at the time of death. One of these patients died after a pulmonary embolus and the other died following an elective chemical pleuradesis for a recurrent pneumothorax. Three patients died of respiratory failure and continuing medical problems without progressing to intubation and ventilation. The decision not to intubate was made in consultation with the patient, family and staff.
Effect of prior surveillance and delay in treatment
There was no significant relationship between previous medical surveillance and survival. There was a higher mortality in those patients regularly attending the outpatient clinic but chi-square analysis did not reveal statistical significance. The patients attending the clinic had a significantly lower CD 4 count on presentation (47 ± 5.7 vs 90 ± 23.8, P < 0.003). This may be the result of the use of prophylactic antimicrobials against P. carinii infection delaying the onset of the disease until later in the course of the underlying illness (Table 3) .
There was no difference between the groups when the delay between onset of symptoms and commencement of treatment was analysed ( Table 4 ). Survival after discharge in the respiratory support group Of the 25 survivors in Group Ill, eighteen were known to be alive at the time of survey. This represents survival of eighteen months in one patient; twelve to eighteen months in seven patients; six to twelve months in six patients and under six months in four patients. The seven hospital survivors in Group III who later died, died 4.9 ± 1.3 months after discharge.
Relationship between bronchoscopy and respiratory failure
The incidence of respiratory failure following bronchoscopy was examined to see if this may have contributed to our survival figures.
Of the 32 patients in Group Ill, only eight had bronchoscopies -three prior to CP AP and five after improvement of the acute attack.
Examination of outcome for the group with deterioration following bronchoscopy reveals that none of the CP AP post-bronchoscopy patients died. If it is hypothesised that respiratory failure following bronchoscopy is a different group with a good prognosis and these patients are excluded, the mortality for the CPAP/IPPV group rises to 7129 (24%). This figure includes the two patients who were intubated and ventilated prior to their demise.
The duration of CP AP in the bronchoscopy patients was 5.0 ± 1.5 days, indicating a similar time course of the disease as for the patients who required CP AP not preceded by bronchoscopy (5.0 ± 0.8 days) and suggests that the respiratory failure was not related to the procedure.
Complication of treatment
The use of CP AP was associated with few complications.
Pneumothorax occurred in three of the 32 patients in the CP AP group. Two of these followed transbronchial biopsy.
Pressure necrosis of the skin of the bridge of the nose in varying degree was experienced by several patients, but healing occurred without sequelae.
Gastric distension occurred occasionally and was relieved by the insertion of a fine 12F gauge silastic nasogastric tube for aspiration. Nasogastric feeding was usually able to be commenced at Day 2. Mortality in CPAP group year to year Table 6 shows the yearly mortality figures for respiratory support patients. The annual numbers are small and make comment difficult, but it can be seen that there is no trend suggesting increased survival since the introduction of routine corticosteroid use in 1989. The mortality before the beginning of 1989 is 20% and after is 22.7%.
DISCUSSION
Previous reports have shown a mortality of 50% to 90% in HIV positive patients with PCP and severe respiratory failure. Wachter reported a mortality of 86% or 87% for patients with PCP who required mechanical ventilation at the San Francisco General Hospital between 1981 and 1985. 5 This led to the general belief that aggressive therapy with admission to intensive care was not justified. Wachter called this 'terminal intensive care'. This controversy continues as illustrated by two recent editorials. 6 ,7' In 1987 we developed a protocol based on the use of mask CP AP in the ward setting for patients in respiratory failure. Results of our retrospective review show a mortality rate for severely affected patients (22%) better than previously recorded.
More recent studies of respiratory failure in HIVassociated PCP have shown an improvement in mortality from 90% to 50% since the introduction of new therapies such as early corticosteroid use. Our results encompass the full period before and after the routine use of corti co steroids and are uninfluenced by the introduction of corticosteroid use.
CP AP has been used for many years in cardiogenic and non-cardiogenic pulmonary oedema. It has previously been shown to be supportive in the AIDS/PCP setting. Gregg et at. 8   TABLE 5 Total group (respiratory support) Resp support not preceded by bronchoscopy Resp support preceded by bronchoscopy reported eighteen patients with AIDS associated PCP and respiratory failure who were treated, as a temporary measure, an average of 4.5 days with CPAP. Hospital mortality was 55% and all patients who progressed to ventilation died. The difference in our protocol is that CP AP was introduced early as the principal mode of therapy with perseverence in the face of fluctuations in the clinical condition. If patients became fatigued, efforts were made to reduce the work of breathing rather than resorting to ventilation.
Are our patients equivalent to those intubated and ventilated in other studies?
It is difficult to be certain that our patients on CP AP are equivalent to patients with respiratory failure in other series who were intubated and ventilated. Implementation of CP AP was carried out at a time when we and other authors would have considered intubation and ventilation because of inability to oxygenate the patient on high-flow oxygen mask.
Examination of the data shows that our patients undergoing mask CP AP are at least similar to those in other reported series. Average P a 0 2 on admission was 49 ± 2.1. The mean respiratory rate was 44 ± 1.5 breaths per minute and the mean Apache Score was 22 ± 0.8. Mask 02 was initially used, and ifP a o 2 of 50 mmHg or Sa02 greater than 90% could not be maintained with high-flow O 2 via face mask, or if respiratory distress persisted, the patient was placed on CP AP. This is similar to data from El-Sadr4 and Friedman 9 for patients who were intubated and ventilated.
EI-Sadr's patients were intubated and commenced on mechanical ventilation because of symptoms and signs of respiratory distress and arterial P02 less than or equal to 50 mmHg on 70% oxygen mask. On admission, his patients had an average Pa02 on room air of 60.6 ± 14.8 for the survivors and 44.8 ± 7.7 for the non-survivors. Friedman defined ARF as a P a o 2 less than 60 mmHg while breathing a gas mixture of at least 40% oxygen or an equivalent Pao2/Fj02 ratio less than 150 mmHg. The P a o 2 /Fj02 ratio of patients requiring positive pressure ventilation in his study was 80.2 ± 6 for the survivors and 78.1 ± 7.1 for the non-survivors immediately prior to ventilation.
There are problems comparing these figures and calculated ratios between studies. The samples are often taken at different stages of the disease and the true Fj02 of a patient on a standard ward oxygen mask is not known due to air entrainment around the mask. Indices such (A-a)D02 and P a o 2 /Fj02 in this setting are meaningless. Despite these difficulties, it can be concluded that our CP AP group had a severe respiratory illness similar to that of intubated patients in previous studies.
Are there any confounding factors?
The records were examined for factors which may have led to more easily reversible respiratory deterioration and less severe pneumonia, which may have improved our survival figures. In previous studies, good prognosis has been associated with short duration of symptoms before admission, low (A-a) 00 2 on room air and bronchoscopy precipitating respiratory failure. El-Sadr found that survivors in his study were symptomatic for only nine days before admission and had P a o 2 of 61 mmHg on room air on admission compared to 23 days and 45 mmHg in the non-survivors. 4 In terms of these statistics our patients are not in the 'good prognosis' group with delay of 18.8 days and P a o 2 of 49 mmHg.
The average figure of 18.8 days between onset of symptoms and commencement of treatment for the whole group is similar to other studies. This is surprising as it was thought that awareness ofPCP among the homosexual community would have resulted in earlier presentation.
Regular surveillance was not found to have a significant correlation with survival. We expected to find that regular surveillance may have helped to detect symptoms of the pneumonia at an early stage, leading to a short delay in treatment, less severe pneumonia and improved survival. In fact, those patients attending the clinic were more symptomatic and had more severe underlying disease as evidenced by the lower CD 4 count in that group. The role of antimicrobial prophylaxis against PCP in altering the clinical course of the disease is uncertain. However, most patients regularly reviewed in a clinic would be prescribed prophylactic agents.
Luce has previously suggested that a high incidence of post-bronchoscopy respiratory failure may distort the results. lo Seven of the eight survivors in the El-Sadr study were admitted to the ICV because their respiratory status deteriorated soon after bronchoscopy. Bronchoscopy in our study was infrequently associated with the precipitation of respiratory failure. If those patients given CP AP following bronchoscopy are excluded, the mortality in Group III stands at 24%. Duration ofCPAP treatment was 5.0 ± 0.8 days in the whole group and 5.0 ± 1.5 days in the post-bronchoscopy group, suggesting the time course of PCP was not altered by the complications ofthe investigations.
Seriously ill patients from 1989 received steroids as part of their management protocol and despite the small numbers in our CP AP group, no change in mortality can be seen for the periods before and after this date ( Table 6 ).
Why are the results better?
It is possible that our results were improved by developing respiratory support which did not require invasive techniques with inherent risk of nosocomial pneumonia in this immunocompromised group of patients. By not invading the airway, not sedating or paralysing the patients, we were able to maintain normal cough, laryngeal reflexes and sputum clearance. By not using intermittent positive pressure ventilation, there may have been less risk of barotrauma, better preservation of surfactant and its geometry. Also, by using a CP AP protocol to avoid contiilUed high inspiratory oxygen concentration, we may have prevented development of oxygen toxicity.
Another factor is that we reviewed only first presentation PCP patients. First presentation PCP would be expected to carry a better prognosis than repeat presentation. El Sadr reviewed first presentation patients,4 one-third of Wachter's patients 5 were second or more presentation and in other studies this detail is not recorded. CONCLUSION Our CP AP protocol for treatment of AIDSassociated PCP arose from the apparent futility of resorting to intubation and ventilation in this condition. We have reviewed our results and found a 22% mortality rate for patients with first presentation PCP and respiratory failure treated with CPAP.
This result is better than previously reported and cannot be explained by apparent aberrations in the patient population or our protocol.
At a time when there is a renewed interest in intensive care for HIV-associated PCP respiratory failure, it is suggested that early intervention with CP AP before the patient tires should be considered. Perseverence with CPAP, despite fluctuations in the patient's condition, may lead to improved survival in these patients.
